Tags : Third

Hope Biosciences Reports its Third US FDA’s Approval for Clinical

Shots:Shots: The company will conduct its third study in collaboration with ADH at River Oaks Hospital and Clinics to determine the role of its HB-adMSCs in decreasing the severity of illness in patients with COVID-19 The P-II study will assess HB-adMSCs vs PBO in patients receiving hydroxychloroquine and azithromycin and not receiving this combination therapy. […]Read More

PharmaShots’ Key Highlights of Third Quarter 2019

The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer’s Research Facility for expansion of its R&D footprints with the acceleration of the development of its biosimilars from lab to pilot scale. Previously, Amgen acquired […]Read More

Eli Lilly’s Taltz (ixekizumab) Receives Third US FDA’s Approval for

Shots: The approval is based on two P-III studies assessing Taltz vs PBO in 657 patients with active AS, randomized into two groups i.e, COAST-V in patients who are bDMARD-naïve and COAST-W in patients who are intolerant or have an inadequate response to TNF inhibitors The two P-III study results: patients achieved ASAS40 @16wks. COAST-V […]Read More

Merck and Eisai’s Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive FDA’s

Shots: The third BT designation is based on P-Ib KEYNOTE-524 study assessing Keytruda (200mg, IV, q3w) + Lenvima (12/8 mg/day) in patients with unresectable HCC not amenable to locoregional treatment The dual regimen has received its first two BT designation for advanced and metastatic renal carcinoma and non-microsatellite instability-high/proficient mismatch repair endometrial carcinoma in Jan’18 […]Read More